Vocal Cord and Muscle Uptake — on Your Neck PET-CT

Not necessarily. Vocal cord uptake is a common, often normal finding caused by muscle activity. Whether it is concerning depends on whether the uptake is symmetrical or one-sided, whether there is a clinical history of cancer in that area, and whether the pattern has changed since your last scan. Your oncologist and radiologist will tell you whether this is physiological or whether it warrants further investigation. Do not try to interpret the finding from the report text alone.

Yes, it does. Speaking during the uptake period — the rest time after your FDG injection — causes vocal cord muscles to contract and absorb more tracer. This makes the vocal cord area appear brighter on the final image and can be mistaken for something significant. If you were talking, answering questions, or on a phone call during that rest period, mention it to your oncology team. It is relevant context that helps them read the finding correctly.

Several things help. Symmetrical uptake on both sides usually reflects muscle use. Focal, one-sided uptake in an area with a cancer history is more suspicious. A measure called SUVmax describes how intensely an area is absorbing FDG, but a high number alone does not confirm disease and a lower number does not rule it out. Comparison with previous scans, the full clinical history, and sometimes a direct examination of the larynx are all part of how a conclusion is reached.

It depends. Symmetrical uptake in someone with no head or neck cancer history usually requires no further test. In someone being monitored after treatment, your oncologist may arrange a laryngoscopy — a camera examination of the vocal cords — or, if the finding is focal and suspicious, a biopsy. The decision is made by your oncologist and radiologist together, based on the full picture rather than the PET-CT finding alone.

Yes, and this is one of the reasons post-treatment PET-CT in head and neck cancer is complex to interpret. Radiation causes changes in normal tissue that can alter FDG uptake in ways that are difficult to distinguish from recurrence. EANM and SNMMI guidance recommends waiting a number of weeks after completing radiotherapy before scanning for response assessment, though the specific timing is guided by your clinical situation rather than a fixed rule. Your oncologist will advise on the right interval for you.

Ask two things: whether the finding is considered physiological or potentially significant, and whether any follow-up is planned. If you were speaking during the uptake period, mention it — it is relevant context. If the finding is new or has changed since a previous scan and your team has not yet addressed it directly, ask specifically about the comparison. Interpreting the report is your oncologist's role. Your role is to give them the full picture of what happened before and during the scan.